Updates are available Correction dated 2025-01-15
Click to view Correction: https://doi.org/10.1038/s41467-025-56017-3
-
Authors
Gao, Vianne R.
Yang, Rui https://orcid.org/0000-0001-9358-9907
Das, Arnav
Luo, Renhe https://orcid.org/0009-0008-1470-4726
Luo, Hanzhi
McNally, Dylan R.
Karagiannidis, Ioannis
Rivas, Martin A. https://orcid.org/0000-0002-9603-6897
Wang, Zhong-Min
Barisic, Darko https://orcid.org/0000-0001-7007-9138
Karbalayghareh, Alireza https://orcid.org/0000-0002-4308-2582
Wong, Wilfred https://orcid.org/0000-0003-1363-5235
Zhan, Yingqian A. https://orcid.org/0000-0002-3548-9227
Chin, Christopher R. https://orcid.org/0000-0002-2140-3197
Noble, William S. https://orcid.org/0000-0001-7283-4715
Bilmes, Jeff A.
Apostolou, Effie https://orcid.org/0000-0002-8111-0863
Kharas, Michael G. https://orcid.org/0000-0002-1165-6991
Béguelin, Wendy https://orcid.org/0000-0002-4894-9229
Viny, Aaron D. https://orcid.org/0000-0001-7039-0110
Huangfu, Danwei https://orcid.org/0000-0002-1145-6199
Rudensky, Alexander Y. https://orcid.org/0000-0003-1280-2898
Melnick, Ari M. https://orcid.org/0000-0002-8074-2287
Leslie, Christina S. https://orcid.org/0000-0002-4571-5910
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (DK128852, HG012103)
- License Information
-
More Information
Article History
Received: 18 October 2023
Accepted: 14 October 2024
First Online: 1 November 2024
Change Date: 15 January 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-025-56017-3
Competing interests
: C.S.L. is an SAB member and co-inventor of IP with Episteme Prognostics, unrelated to the current study. M.G.K is a member of the scientific advisory board of 858 Therapeutics and the laboratory gets research support from AstraZeneca and Transition Bio. A.D.V. is an SAB member of Arima Genomics. A.Y.R. is an SAB member and has equity in Sonoma Biotherapeutics, Santa Ana Bio, RAPT Therapeutics, and Vedanta Biosciences. He is an SEB member of Amgen and BioInvent and is a co-inventor or has IP licensed to Takeda that is unrelated to the content of the present study. A.M.M. has research funding from Janssen, Epizyme, and Daiichi Sankyo. A.M.M. has consulted for Exo Therapeutics, Treeline Biosciences, and AstraZeneca. The remaining authors declare no competing interests.
